Morgan Stanley keeps GBP 2.88 target for ConvaTec stock

Published on 10/17/2026 at 19:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 2026 operating margin reached 21.20 percent after 5.00 percent organic growth. ConvaTec stock costs EUR 2.80 on October 16, 2026, up 0.51 percent on LSE.

Analyst target and reporting date

Morgan Stanley maintained a GBP 2.88 target on October 9, 2026.
ConvaTec reported 5.00 percent organic revenue growth and a 21.20 percent operating margin in the first half of 2026.
ConvaTec stock costs EUR 2.80 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST, up 0.51 percent on the London Stock Exchange.
ConvaTec is scheduled to publish its next earnings report on February 23, 2027.

ConvaTec, GB00BD3VFW73, Illustration mit AI erstellt.

Morgan Stanley maintained a Buy rating and a GBP 2.88 price target for ConvaTec on October 9, 2026, according to Investing.com. The target implies 21.01 percent upside from the LSE price of GBP 2.38. The stock was last at EUR 2.80 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.

First-half growth supports the target

ConvaTec reported 5.00 percent organic revenue growth in the first half of 2026, excluding InnovaMatrix, while operating margin reached 21.20 percent and earnings per share increased 6.00 percent. The company also reaffirmed full-year 2026 guidance for an operating margin of at least 23.00 percent and double-digit earnings-per-share growth, according to Investing.com. The margin comparison gives investors a clear measure for judging the second half against the 21.20 percent first-half outcome.

Stock stays below yearly high

The LSE price was GBp 238.00 on October 16, 2026, up 0.51 percent from the prior close of GBp 236.80. ConvaTec traded between GBp 234.20 and GBp 239.40 during that session, with volume of 7.26 million shares against an average of 8.30 million. Its 52-week range was GBp 193.00 to GBp 259.20, leaving the price 8.18 percent below the high.

Valuation and next reporting date

ConvaTec had a market capitalization of GBP 4.6 billion, a trailing P/E ratio of 50.83 and a dividend yield of 2.00 percent on October 16, 2026. The valuation sits above Smith & Nephew's P/E ratio of 19.53, while ConvaTec's 2026 operating-margin guidance provides the central benchmark for the earnings outlook.

ConvaTec is scheduled to publish its next earnings report on February 23, 2027, according to Investing.com.

Comparison with peers

ConvaTec: plus 0.51 percent, P/E 50.83, market capitalization GBP 4.6 billion.

Smith & Nephew (LSE, GBp): minus 0.32 percent, P/E 19.53, market capitalization GBP 9.1 billion.

Coloplast (Nasdaq Copenhagen, DKK): plus 0.79 percent, P/E 38.52, market capitalization DKK 106.4 billion.

What the figures imply

The market is assigning ConvaTec a higher earnings multiple than Smith & Nephew, while its first-half operating margin of 21.20 percent remains below the full-year guidance floor of 23.00 percent. That gap makes the next reporting date important for measuring whether the margin target is translating into operating progress.

Price and market position

ConvaTec's euro quotation remains an after-hours indication for investors in Germany, while the completed LSE session provides the latest home-market comparison. The GBp 259.20 high and the GBP 2.88 Morgan Stanley target offer two separate reference levels for assessing the stock's position.

The latest price was EUR 2.80 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of ConvaTec stock.